Literature DB >> 16466920

New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity.

Petr Dzubák1, Marián Hajdúch, Radek Gazák, Alena Svobodová, Jitka Psotová, Daniela Walterová, Petr Sedmera, Vladimír Kren.   

Abstract

Large series of O-alkyl derivatives (methyl and benzyl) of silybin and 2,3-dehydrosilybin was prepared. Selective alkylation of the silybin molecule was systematically investigated. For the first time we present here, for example, preparation of 19-nor-2,3-dehydrosilybin. All prepared silybin/2,3-dehydrosilybin derivatives were tested for cytotoxicity on a panel of drugs sensitive against multidrug resistant cell lines and the ability to inhibit P-glycoprotein mediated efflux activity. We have identified effective and relatively non-cytotoxic inhibitors of P-gp derived from 2,3-dehydrosilybin. Some of them were more effective inhibitors at concentrations lower than a standard P-gp efflux inhibitor cyclosporin A. Another group of 2,3-dehydrosilybin derivatives also had better inhibitory effects on P-gp efflux but a cytotoxicity comparable with that of parent 2,3-dehydrosilybin. Structural requirements for improving inhibitory activity and reducing toxicity of 2,3-dehydrosilybin were established. Effect of E-ring substitution as well as an influence of the substituent size at the C-7-OH position of A-ring on P-gp-inhibitory activity was evaluated for the first time in this study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16466920     DOI: 10.1016/j.bmc.2006.01.035

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  20 in total

1.  5- or/and 20-O-alkyl-2,3-dehydrosilybins: Synthesis and biological profiles on prostate cancer cell models.

Authors:  Bao Vue; Xiaojie Zhang; Timmy Lee; Nandini Nair; Sheng Zhang; Guanglin Chen; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Bioorg Med Chem       Date:  2017-07-20       Impact factor: 3.641

2.  A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.

Authors:  Fabio Broccatelli; Emanuele Carosati; Annalisa Neri; Maria Frosini; Laura Goracci; Tudor I Oprea; Gabriele Cruciani
Journal:  J Med Chem       Date:  2011-02-22       Impact factor: 7.446

Review 3.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

Review 4.  Novel molecules as the emerging trends in cancer treatment: an update.

Authors:  Priyanka Sekar; Raashmi Ravitchandirane; Sofia Khanam; Nethaji Muniraj; Ananda Vayaravel Cassinadane
Journal:  Med Oncol       Date:  2022-01-04       Impact factor: 3.064

5.  Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.

Authors:  Bao Vue; Sheng Zhang; Xiaojie Zhang; Konstantinos Parisis; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Eur J Med Chem       Date:  2015-12-24       Impact factor: 6.514

Review 6.  Multitargeted therapy of cancer by silymarin.

Authors:  Kumaraguruparan Ramasamy; Rajesh Agarwal
Journal:  Cancer Lett       Date:  2008-05-09       Impact factor: 8.679

7.  3-O-Alkyl-2,3-dehydrosilibinins: Two synthetic approaches and in vitro effects toward prostate cancer cells.

Authors:  Sheng Zhang; Bao Vue; Michael Huang; Xiaojie Zhang; Timmy Lee; Guanglin Chen; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Bioorg Med Chem Lett       Date:  2016-05-24       Impact factor: 2.823

8.  Enhanced bioactivity of silybin B methylation products.

Authors:  Arlene A Sy-Cordero; Tyler N Graf; Scott P Runyon; Mansukh C Wani; David J Kroll; Rajesh Agarwal; Scott J Brantley; Mary F Paine; Stephen J Polyak; Nicholas H Oberlies
Journal:  Bioorg Med Chem       Date:  2012-12-05       Impact factor: 3.641

Review 9.  Lung Cancer Management with Silibinin: A Historical and Translational Perspective.

Authors:  Sara Verdura; Elisabet Cuyàs; Verónica Ruiz-Torres; Vicente Micol; Jorge Joven; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11

10.  Anti-cancer efficacy of silybin derivatives -- a structure-activity relationship.

Authors:  Chapla Agarwal; Ritambhara Wadhwa; Gagan Deep; David Biedermann; Radek Gažák; Vladimír Křen; Rajesh Agarwal
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.